We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
-9.41%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$982M
AUM Growth
+$21.4M
Cap. Flow
+$184M
Cap. Flow %
18.72%
Top 10 Hldgs %
37.6%
Holding
143
New
43
Increased
40
Reduced
5
Closed
15

Top Buys

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$29.1M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$19.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$15.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$15.4M
5
TDOC icon
Teladoc Health
TDOC
+$12.2M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$24.5M
2
MOR
MorphoSys AG American Depositary Shares
MOR
+$14.5M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$9.44M
4
NTLA icon
Intellia Therapeutics
NTLA
+$5.5M
5
BLUE
bluebird bio
BLUE
+$3.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.92%
2 Technology 1.53%
3 Real Estate 0.71%
4 Communication Services 0.66%
5 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DEI icon
76
Douglas Emmett
DEI
$1.96B
$2.28M 0.23%
+171,138
New +$2.32M
KURA icon
77
Kura Oncology
KURA
$850M
$2.06M 0.21%
100,000
– –
BCAB icon
78
BioAtla
BCAB
$5.74M
$1.88M 0.19%
27,482
-2,000
-7% -$238K
CHRS icon
79
Coherus Oncology
CHRS
$196M
$1.82M 0.19%
+1,050,000
New +$2.11M
TGTX icon
80
TG Therapeutics
TGTX
$7.62B
$1.78M 0.18%
100,000
– –
MCRB icon
81
Seres Therapeutics
MCRB
$48.4M
$1.74M 0.18%
120,356
+75,000
+165% +$1.25M
ADAP
82
DELISTED
Adaptimmune Therapeutics
ADAP
$1.7M 0.17%
1,743,619
+300,000
+21% +$329K
VSTM icon
83
Verastem
VSTM
$610M
$1.61M 0.16%
541,514
– –
LKFT
84
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$1.38M 0.14%
+55,609
New +$1.58M
ABCL icon
85
AbCellera Biologics
ABCL
$2.12B
$1.37M 0.14%
+461,699
New +$1.75M
TECX
86
Tectonic Therapeutic
TECX
$606M
$1.3M 0.13%
79,166
+8,099
+11% +$130K
ERAS icon
87
Erasca
ERAS
$6.39B
$1.3M 0.13%
550,000
+450,000
+450% +$971K
PASG icon
88
Passage Bio
PASG
$14.1M
$1.19M 0.12%
75,000
– –
OABI icon
89
OmniAb
OABI
$447M
$1.13M 0.11%
+300,000
New +$1.37M
QNCX icon
90
Quince Therapeutics
QNCX
$29.5M
$1.13M 0.11%
7,500
-7,238
-49% -$1.31M
ATYR
91
aTyr Pharma
ATYR
$50.1M
$1.05M 0.11%
671,134
+200,000
+42% +$348K
RVNC
92
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.03M 0.1%
400,000
+200,000
+100% +$683K
NXTC icon
93
NextCure
NXTC
$26.7M
$959K 0.1%
50,250
+38,207
+317% +$743K
MGNX icon
94
MacroGenics
MGNX
$257M
$930K 0.09%
+218,856
New +$2.13M
CCCC icon
95
C4 Therapeutics
CCCC
$412M
$924K 0.09%
+200,000
New +$1.19M
ATXS
96
DELISTED
Astria Therapeutics
ATXS
$910K 0.09%
+100,000
New +$976K
DERM icon
97
Journey Medical
DERM
$177M
$837K 0.09%
148,322
+9,697
+7% +$39.9K
RLMD icon
98
Relmada Therapeutics
RLMD
$527M
$714K 0.07%
237,874
+237,492
+62,171% +$859K
TYRA icon
99
Tyra Biosciences
TYRA
$1.58B
$675K 0.07%
+42,223
New +$727K
EGRX
100
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$666K 0.07%
118,857
– –
2 3
4
5 6

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Tang Capital Management held 143 positions worth $982M, up 2.2% from $960M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tang Capital Management deployed $184M of net new capital in Q2 2024, opening 43 new positions and adding to 40 existing holdings. Its largest new stake was Dynavax Technologies: 2,500,000 shares worth $28.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Technology and Real Estate.

On the sell side, the largest reduction was Quince Therapeutics, an estimated $1.31M trimmed.

  • Tang Capital Management's largest Q2 2024 buy was Dynavax Technologies: 2,500,000 shares worth $28.1M.
  • Tang Capital Management added most to ANI Pharmaceuticals in Q2 2024, an estimated $19.5M increase.
  • Tang Capital Management's biggest Q2 2024 reduction was Quince Therapeutics, cutting an estimated $1.31M.
  • Tang Capital Management fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $24.5M.
  • Tang Capital Management's ten largest holdings make up 38% of its $982M portfolio in Q2 2024.
  • Tang Capital Management opened 43 new positions and closed 15 in Q2 2024.
  • Tang Capital Management's portfolio value rose 2.2% quarter-over-quarter to $982M.

Based on Tang Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.